Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Oncology Ranking and Detailed Regulatory Approval Profiles of 157 Cancer Drugs 1985-2016 - Research and Markets

Research and Markets
Posted on: 21 Oct 16

Research and Markets has announced the addition of the "Oncology: Ranking and Detailed Regulatory Approval Profiles - 157 Cancer Drugs (1985-2016)" report to their offering.

Oncology: Ranking and detailed regulatory approval profiles - 157 cancer drugs (1985-2016) is a comprehensive drug ranking and profiling report that ranks cancer drugs based on total approvals and unique approvals received in US, Europe and Japan. It provides the regulatory approval details of each drug for the past 30 years (1985-2016) in both the tabular and (an interesting) infographic formats.

Additionally, the basic drug-specific information such as first approvals, breakthrough, orphan designations, black box warnings, etc., is also presented along with negative developments of drugs recalled, discontinued and withdrawn.

We have screened and segmented 157 drugs (from a list of 250 approved cancer drugs) based on the criteria of at least one new or additional approval in the past decade. This report gives detailed information about these drugs and their approval histories from all the three regulatory bodies, namely, the US-based United States Food and Drugs Authority (USFDA), Europe-based European Medicines Agency (EMA) and Japan-based Pharmaceuticals and Medical Devices Agency (PMDA).

The report is divided into two broader sections (Ranking and Drug Profiles) and several sub-sections.

Each drug in the drug profile section is described in the following three parts:

Part 1: The basic information section covers:

Trade names: Drugs are often known by different brand names (trade names) in different geographies. For instance, Rituxan is the trade name for Rituximab in the US, whereas it is known as Mabthera in Europe. We have presented each drug's trade name used in different geographies in our report.

Part 2: The approval timeline infographic

It is a graphical representation of approval history with date of approval, type of approval, indications, designations and lines of treatment.

Part 3: Approval history tables

Drug approvals by USFDA, EMA and PMDA show detailed indications, broader indications, approval dates, in combination with, treatment preference and orphan designation dates. We have highlighted the unique indications in bold. Withdrawn and discontinued approvals are highlighted in red in the infographic and the tables. For all the drugs, we have excluded approvals related to non-oncology and benign tumor indications.

We have sequenced 157 drugs into six segments based on total number of approvals:

  • Segment A - 25+ approvals
  • Segment B - 15 to 24 approvals
  • Segment C - 10 to 14 approvals
  • Segment D - 5 to 9 approvals
  • Segment E - 2 to 4 approvals
  • Segment F - only one approval.

Similarly, drugs are ranked in various segments based on unique approvals.

Companies Mentioned (Partial List)

  • Abbvie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Celgene
  • Chugai
  • Clinigen Healthcare
  • Daiichi Sankyo
  • Depomed
  • Eisai
  • Eli Lilly
  • Endo Pharma
  • GSK
  • Gilead Sciences
  • Heron Therapeutics
  • Hisamitsu
  • Meda Pharma
  • Merck KgaA
  • Merrimack Pharmaceuticals
  • Midatech Pharma
  • Minophagen pharma
  • Mundipharma
  • Nippon Shinyaku
  • Nova Laboratories
  • Novartis
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi
  • Shire
  • Spectrum Pharma
  • Valeant
  • Yakult Honsha

For more information about this report visit

View source version on

Business Wire

Last updated on: 21/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.